

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 January 2003 (30.01.2003)

PCT

(10) International Publication Number
WO 03/008387 A1


- (51) International Patent Classification⁷: **C07D 239/69**, 403/12, A61K 31/635, A61P 9/10, 9/12
- (74) Agent: **TURUN PATENTTITOIMISTO OY**; P.O. Box 99, FIN-20521 Turku (FI).
- (21) International Application Number: **PCT/FI02/00643**
- (22) International Filing Date: **22 July 2002 (22.07.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
20011560 20 July 2001 (20.07.2001) FI
60/306,449 20 July 2001 (20.07.2001) US
- (71) Applicant (for all designated States except US): **OY JUVANTIA PHARMA LTD [FI/FI]**; Lemminkäisenkatu 5, FIN-20520 Turku (FI).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **JOUTSAMO, Topi [FI/FI]**; Kohmontie 10 B 37, FIN-20540 Turku (FI).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

Puolikontie 6 C, FIN-20300 Turku (FI). **HOFFRÉN, Anna-Marja [FI/FI]**; Bilmarkinkatu 4 as 12, FIN-20100 Turku (FI). **WURSTER, Siegfried [DE/FI]**; Matarakaari 28 A 1, FIN-21500 Piikkiö (FI).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **COMPOUNDS USEFUL FOR TREATMENT OR PREVENTION OF DISEASE MEDIATED BY ALPHA-2B-ADRENOCEPTOR**



(57) Abstract: The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R₁, R₂, R₃, R₄ and R₅ are independently of each other H, a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen; X is H, a straight or branched alkyl chain with 1 to 4 carbon atoms, phenyl, -OH or =O; Z is H, acetyl, -CH₂-Ph-O-CF₃ or CH₂-Ph-CF₃, Y is a ring structure optionally linked to formula (I) with an alkyl chain having one or two carbon

atoms. This invention further relates to the use of said compounds for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal.

WO 03/008387 A1

BEST AVAILABLE COPY

COMPOUNDS USEFUL FOR TREATMENT OR PREVENTION OF DISEASE MEDIATED BY ALPHA-2B-ADRENOCEPTOR

The present invention relates to the use of selective alpha-2B-adrenoceptor antagonists for the manufacture of a pharmaceutical preparation useful for the
5 treatment or prevention of diseases mediated by the alpha-2B-adrenoceptor in mammals.

BACKGROUND OF THE INVENTION


The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the
10 practice, are incorporated by reference.

It is known that alpha-2B-adrenoceptors mediate vascular contractions. Therefore, alpha-2B-antagonists are useful in the treatment or prevention of diseases involving vascular contraction. It has also been found that certain individuals have a genetic polymorphism in the alpha-2B-adrenoceptor gene. It has been observed
15 that the alpha-2B-adrenoceptor protein in some subjects has a deletion of 3 glutamates from the glutamic acid repeat element of 12 glutamates (amino acids 297–309), in an acid stretch of 17 amino acids, located in the third intracellular loop of the receptor polypeptide (WO 01/29082; Heinonen et al., 1999).

OBJECTS AND SUMMARY OF THE INVENTION

20 An object of this invention is to provide compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal.

Thus this invention concerns a novel compound of formula (I)



or a pharmaceutically acceptable salt thereof.

R_1 , R_2 , R_3 , R_4 and R_5 are independently of each other H, a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

5 X is H, a straight or branched alkyl chain with 1 to 4 carbon atoms, phenyl or -OH;

Z is H, acetyl, $-\text{CH}_2\text{-Ph-O-CF}_3$ or $-\text{CH}_2\text{-Ph-CF}_3$, where Ph is phenyl;

Y is a ring structure optionally linked to formula (I) with an alkyl chain having

10 a) phenyl optionally mono- or disubstituted and each substituent is independently selected from the group consisting of a halogen, a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, a halogen substituted methyl or methoxy group, a nitrile, an amide, amino, or a nitro group;


15 b) 2-benzimidazolyl, 2-imidazolyl, or 2- or 3-indolyl, wherein one N optionally has a substituent that is a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, or benzyl; and wherein the 2-benzimidazolyl, 2-imidazolyl, or 2- or 3-indolyl is optionally mono- or disubstituted and each substituent can independently be a straight or
20 branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

(c) pyridinyl optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen; or

(d) naphthyl optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen.

The following previously known compounds are excluded: 4-[(1*H*-benzimidazol-2-ylmethyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide
 5 (Kumar & Reddy, 1985), *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-methyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide (No 653716, ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127) and
 10 *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide (No AE-848/34956037, SPECS and BioSPECS B. V., Fleminglaan 16, 2289 CP Rijswijk, The Netherlands) and *N*-(4-methyl-2-pyrimidinyl)-4-[(1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide
 (Frag & El-Mouafi & Khalifa, 1991).

THIS INVENTION FURTHER CONCERNS USE OF COMPOUNDS OF FORMULA (I)



15

or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal wherein

15 **R₁** , **R₂** , **R₃** , **R₄** and **R₅** are independently of each other H , a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

20

X is H , a straight or branched alkyl chain with 1 to 4 carbon atoms, phenyl, -OH or =O ;

Z is H, acetyl, -CH₂-Ph-O-CF₃ or -CH₂-Ph-CF₃ , where Ph is phenyl;


Y is a ring structure optionally linked to formula (I) with an alkyl chain having one or two carbon atoms, wherein the ring structure is

- 5 a) phenyl optionally mono- or disubstituted and each substituent is independently selected from the group consisting of a halogen, a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, a halogen substituted methyl or methoxy group, an acetyl, a nitrile, an amide, amino, or a nitro group;
- 10 b) 2-benzimidazolyl, 2-imidazolyl, or 2- or 3-indolyl, wherein one N optionally has a substituent that is a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, or benzyl; and wherein the 2-benzimidazolyl, 2-imidazolyl, or 2- or 3-indolyl is optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;
- 15 ~~(c) pyridinyl optionally mono- or disubstituted and each substituent can~~ independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen; or
- (d) naphthyl optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen.
- 20 The following compounds previously known to be selective alpha-2B-adrenoceptor antagonists are excluded: *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-methyl-1*H*-benzimidazol-2-ylmethyl)-amino] -benzenesulfonamide (No 653716, ChemBridge Corporation, 16981 Via Tazon, Suite G, San Diego CA 92127), *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-benzimidazol-2-ylmethyl)-amino] -benzenesulfonamide (No AE-848/34956037, SPECS and
- 25 BioSPECS B. V., Fleminglaan 16, 2289 CP Rijswijk, The Netherlands) and *N*-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-4-ethoxy-benzamide (No AF-

399/36012031, SPECS and BioSPECS B. V., Fleminglaan 16, 2289 CP Rijswijk, The Netherlands).

DETAILED DESCRIPTION OF THE INVENTION

Preferred compounds of the invention are compounds of formula (I)



5

as defined in the preceding summary or pharmaceutically acceptable salts thereof wherein R_1 and R_3 are methyl and R_2 , R_4 and R_5 are H.

In some preferable compounds X is H, Y is a phenyl optionally mono- or disubstituted with a straight or branched alkoxy group and Z is H. Compounds fulfilling all of the aforementioned characteristics and wherein said phenyl is substituted and said alkoxy substituent is methoxy are

4-(2,4-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(3-methoxybenzylamino)-benzenesulfonamide, 4-(3,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(2,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide and *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2-methoxybenzylamino)-benzenesulfonamide.

In other preferred compounds X is H, Y is a phenyl optionally mono- or disubstituted with a straight or branched alkyl and/or a halogen and Z is H. These comprise compounds such as 4-benzylamino-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2-methylbenzyl-


20

amino)-benzenesulfonamide, 4-(2,4-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(3-methylbenzylamino)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(4-methylbenzylamino)-benzenesulfonamide, 4-(2,5-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(2,6-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(4-bromobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide and 4-(2,6-dichlorobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide.

Further preferred compounds are *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-indol-3-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-isobutyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(1-phenylethylamino)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[2-(2-methoxyphenyl)-ethylamino]-benzenesulfonamide.

According to one embodiment of the invention the compound is *N*-(4-methyl-2-pyrimidinyl)-4-[(1-methyl-1*H*-benzimidazol-2-yl)-methyl]amino]-benzenesulfonamide.

The invention also relates to the use of selective alpha-2B-adrenoceptor antagonists of formula (I)



as defined in the preceding summary, or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation.

In many preferable compounds to be used R_1 and R_3 are typically methyl and R_2 , R_4 and R_5 are typically H.

- 5 In some compounds preferably used X is H, Y is a phenyl optionally mono- or disubstituted with a straight or branched alkoxy group and Z is H. Especially preferable for use are compounds in which said phenyl is substituted and said alkoxy substituent is methoxy. Such compound comprise 4-(2,4-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-
 10 (4,6-dimethylpyrimidin-2-yl)-4-(3-methoxybenzylamino)-benzenesulfonamide, 4-(3,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(2,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(2,6-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(4-methoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide.
- 15 In other compounds preferably used X is H, Y is a phenyl optionally mono- or disubstituted with a straight or branched alkyl and/or a halogen and Z is H. Such compound comprise 4-benzylamino-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2-methylbenzylamino)-benzenesulfonamide, 4-(2,4-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-
 20 benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(3-methylbenzylamino)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(4-methylbenzylamino)-benzenesulfonamide, 4-(2,5-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(2,6-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(4-bromobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide
 25 and 4-(2,6-dichlorobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide.

Further preferred compounds to be used comprise 4-[(1*H*-benzimidazol-2-ylmethyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-indol-3-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-isobutyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(1-phenylethylamino)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[2-(2-methoxyphenyl)-ethylamino]-benzenesulfonamide and *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(naphthalen-2-ylmethyl)-amino]-benzenesulfonamide.

Alpha-2B-adrenoceptor antagonists are useful in the treatment and/or prevention of many diseases.

Individuals having a deletion in the alpha-2B-adrenoceptor protein (WO 01/29082; Heinonen et al., 1999), particularly the deletion/deletion genotype (D/D genotype)

alpha-2B-adrenoceptor antagonists. These individuals have a deletion of 3 glutamates from the glutamic acid repeat element of 12 glutamates (amino acids 297–309), in an acid stretch of 17 amino acids, located in the third intracellular loop of the receptor polypeptide.

It has been found that in a population-based cohort of Finnish middle-aged men that subjects with a D/D genotype of the alpha-2B-adrenoceptor gene have a significantly elevated risk for acute myocardial infarction (AMI) in a five-year follow-up study. The risk for AMI was increased in subjects who had no previously diagnosed coronary heart disease (CHD) at the study outset. Therefore, it has been postulated that the D/D genotype is related to an impaired capacity to down-regulate alpha-2B-adrenoceptor function during sustained receptor activation. Therefore, alpha-2B-adrenoceptors are believed to be involved in the pathogenesis of a significant fraction of all cases of AMI, especially in subjects

with the D/D genotype, but also in I/D and I/I subjects (I means "insertion" and stands for the "normal" allele).

The alpha-2B-adrenoceptor antagonists as disclosed in this invention would be particularly useful in the treatment or prevention of coronary heart diseases. As

5 examples can be mentioned

a) Acute AMI

If alpha-2B-adrenoceptor dependent vasoconstriction is a causative factor in some cases of AMI, then antagonism of these receptors should restore coronary circulation and reduce the ischemic myocardial damage.

10 b) Unstable angina pectoris

An alpha-2B-adrenoceptor antagonist will relieve the vasoconstrictive component in the sustained ischemic episode, thus alleviating the symptoms

c) Prinzmetal's variant form of angina pectoris

15 Vasoconstriction is a key factor in the pathogenesis of Prinzmetal's angina, and an alpha-2B- adrenoceptor antagonist may resolve and prevent attacks.

d) Other forms of chronic angina pectoris and CHD

20 An alpha-2B-adrenoceptor antagonist will help to alleviate the vasoconstrictive component in all types of CHD, providing both symptomatic relief and protection from AMI. A general reduction in vascular tone will contribute to this by reducing venous return, cardiac workload and oxygen consumption (a nitrate-type effect; see below).

e) Prevention of restenosis after coronary angioplasty in cases where vasoconstriction plays a role in restenosis.

25 Furthermore, the alpha-2B-adrenoceptor antagonists as disclosed in this invention would be useful in the treatment or prevention of essential hypertension, especially

in subjects with increased sympathetic activity and a hyperdynamic circulatory system.

In the study mentioned above, the D/D variant of the alpha-2B-adrenoceptor gene was not clearly associated with blood pressure. The inventors believe that this was
5 due to two main factors, 1) antihypertensive treatment, and 2) complex regulation of systemic blood pressure. In another study (Heinonen et al.), it was observed that the D/D genotype was associated with reduced basal metabolic rate and reduced heart rate. These associations probably reflect increased vascular resistance in these subjects.

10 In transgenic mice with targeted inactivation of the alpha-2B-adrenoceptor gene, intravenously administered alpha-2-adrenoceptor agonists fail to induce the characteristic blood pressure elevation, which is seen in normal animals and also in human. Standard doses of such drugs (Glick et al., 1996). The hypertensive
15 effect of these drugs was markedly accentuated. This demonstrates that alpha-2B-adrenoceptors mediate vascular contraction. Thus, an antagonist should reduce blood pressure. This effect has not been seen with alpha-2B-non-selective alpha-2-adrenoceptor antagonists, because antagonism of alpha-2A-adrenoceptors increases sympathetic outflow, cardiac output and blood pressure. In mice with dysfunctional alpha-2A-adrenoceptors, alpha-2-adrenoceptor agonists caused an
20 accentuated hypertensive response and no hypotension (MacMillan et al., 1996).

An alpha-2B-adrenoceptor antagonist is postulated to have favourable effects in hypertensive subjects through their effects on renal function, muscle blood flow, and also on vascular resistance in other vascular beds. The anti-AMI effect of such a drug will be an additional benefit, as hypertension is a significant risk factor for
25 AMI. This protection is due to three factors: 1) a reduction in systemic blood pressure, 2) decreased risk of coronary vasoconstriction, and 3) a nitrate-like effect on venous return, myocardial workload and oxygen consumption.

Moreover, the alpha-2B-adrenoceptor antagonists as disclosed in this invention would be useful in the treatment or prevention of other vascular diseases. Specifically, benefits can be expected in the treatment or prevention of

- vasoconstriction and hypoxic brain damage subsequent to subarachnoid
- 5 haemorrhage,
- migraine,
- Raynaud's disease and cold intolerance,
- pre-eclampsia,
- male erectile dysfunction, and
- 10 - obesity and the metabolic syndrome.

The last mentioned effect is due to the fact that reduced muscle blood flow and reduced basal metabolic rate contribute to the development of obesity and hypertension. An alpha-2B-adrenoceptor antagonist will, by increasing the muscle

- 15 favourable direction.

The alpha-2B-adrenoceptor antagonists disclosed in this invention are also useful in anaesthesia and analgesia to potentiate the clinical efficacy of alpha-2-adrenoceptor agonists, which are not selective for the alpha-2B-adrenoceptor subtype. By blocking the vasoconstriction induced by these agonists, a

20 simultaneously administered alpha-2B-adrenoceptor antagonist will allow the use of larger doses of said agonists, up to anaesthetic dose levels which have not previously been possible in man, only in veterinary anaesthetic practice.

EXPERIMENTAL SECTION

Human alpha-2-adrenoceptor binding affinity

The affinity of test compounds for the three human α_2 -adrenoceptor subtypes (α_{2A} , α_{2B} and α_{2C}) was determined in competition binding assays with ^3H -rauwolscine.

- 5 The biological material for these experiments consisted of membranes from Shionogi S115 cells stably transfected with any of the three human α_2 subtypes (Marjamäki et al. 1992). Membrane (5–10 μg of total protein per sample) and 1–2 nM ^3H -rauwolscine (specific activity 78 Ci/mmol) were incubated in 50 mM KH_2PO_4 , pH 7.5 with 6 concentrations of the compounds. Each concentration was
- 10 run in duplicate. Non-specific binding was defined by 100 μM oxymetazoline and corresponded to 5–15% of total binding. After 30 min at room temperature, incubations were terminated by rapid vacuum filtration through GF/B glass fiber filter and three times with ice-cold incubation buffer. The filters were then
- dried, impregnated with scintillate and their radioactivity was measured by
- 15 scintillation counting. The analysis of the experiments was carried out by non-linear least square curve fitting. Experimentally determined IC_{50} values were converted to K_i 's by making use of the Cheng-Prusoff equation (Cheng and Prusoff, 1973). Experiments were repeated a minimum of three times.

Table 1: Human α_2 -adrenoceptor subtypes binding affinities. Data is presented as

20 K_i 's in nM (Mean \pm SEM).

Compound	alpha-2A	alpha-2B	alpha-2C
A	>13000	160 \pm 20	>30000
B	>4500	34 \pm 2	>10000
C	2000 \pm 400	10 \pm 2	>10000
D	>10000	440 \pm 70	>10000
E	>5100	20 \pm 4	>10000

F	>4300	43 ± 7	>10000
G	2200 ± 600	32 ± 5	>10000
H	>30000	8000 ± 500	>30000

Results expressed in the form of ">" means that no numerical values for K_i 's could be established due to lack of displacement or due to incomplete competition curves. However, the experimental data indicated that, at a minimum, the K_i 's must be larger than the numbers given.

5 Antagonist activity on human α -2-adrenoceptor subtypes

Antagonist potencies were determined as the ability of test compounds to competitively inhibit epinephrine-stimulated ^{35}S -GTP γ S binding to G proteins (Tian et al., 1993; Wieland and Jakobs, 1994; Jasper et al., 1998) in membranes of CHO cells stably transfected with one of the three human α -subtypes (Pohjanpelto et al., 1997; Marjamäki et al., 1998). Membranes (2–6 μg of protein per sample) and 12 concentrations of test compound were preincubated for 30 min with a fixed concentration of epinephrine (5 μM for α_{2A} , 15 μM for α_{2B} , 5 μM for α_{2C}) in 50 mM Tris, 5 mM MgCl_2 , 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 10 μM GDP, 30 μM ascorbic acid, pH 7.4 at room temperature. Binding of radiolabel was started by the addition of trace amounts of ^{35}S -GTP γ S (0.08–0.15 nM, specific activity 1250 Ci/mmol) to the incubation mixture. After an additional 60 min at room temperature, the incubation was terminated by rapid vacuum filtration through glass fibre filter. Filters were washed three times with 5 ml ice cold wash buffer (20 mM Tris, 5 mM MgCl_2 , 1 mM EDTA pH 7.4 at room temperature), dried and counted for radioactivity in a scintillation counter. Analysis of experiments was carried out by non-linear least square fitting. Results are based on a minimum of three experiments.

Table 2: Antagonist effect on human α_2 -adrenoceptor subtypes. Data is presented as KB's in nM (Mean \pm SEM).

Compound	alpha-2A	alpha-2B	alpha-2C
B	14500 \pm 3600	75 \pm 9	5700 \pm 700
C	5400 \pm 1400	17 \pm 5	6300 \pm 1400
E	7900 \pm 3100	29 \pm 5	7300 \pm 1100
F	8700 \pm 1100	240 \pm 60	12000 \pm 2000
G	3200 \pm 500	86 \pm 64	4700 \pm 1800

For the purpose of the invention, the alpha-2B-adrenoceptor antagonist or its pharmaceutically acceptable salt can be administered by various routes. The suitable administration forms include, for example, oral formulations; parenteral injections including intravenous, intramuscular, intradermal and subcutaneous injections; transdermal or rectal administration forms. The required dosage of the compounds of the alpha-2B-adrenoceptor antagonist will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed. The suitable dose varies in the range 5 μ g to 100 mg per kg body weight and day for an adult person.

EXAMPLES

Example 1

N-(4,6-Dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-benzimidazol-2-yl)methyl]-amino]-benzenesulfonamide

5 *Step I: Alkylation of 2-hydroxymethylbenzimidazole*

99.2 mg (0.67 mmol) 2-hydroxymethylbenzimidazole was dissolved in 3 ml methanol. Potassium carbonate (103.1 g, 0.75 mmol) and diethylsulfate (442 µl 3.38 mmol) were added to the reaction mixture. Solution was stirred and refluxed overnight. The reaction mixture was then evaporated to dryness and purified on
10 silica using gradient elution (chloroform to 5% methanol in chloroform) to obtain

Step II: Chlorination of 1-ethyl-2-hydroxymethylbenzimidazole

20 mg (0.11 mmol) 1-ethyl-2-hydroxymethylbenzimidazole was dissolved in 2 ml dichloromethane. Thionyl chloride (24 µl, 0.33 mmol) was diluted 20 times with
15 dichloromethane and the solution was added to the reaction mixture. Reaction mixture was stirred at room temperature for two hours, evaporated to dryness and washed with water to yield 1-ethyl-2-chloromethylbenzimidazole as pale yellow crystals, 36 mg (95%).

20 *Step III: Coupling reaction between 1-ethyl-2-chloromethylbenzimidazole and sulfamethazine*

32.4 mg (0.12 mmol) sulfamethazine and 36 mg (0.18 mmol) 1-ethyl-2-chloromethylbenzimidazole were dissolved in 4 ml methanol. 64 µl (0.44 mmol) triethylamine and catalytic amount of sodium iodide were added to the reaction

mixture. Solution was stirred and refluxed overnight. The reaction mixture was then evaporated to dryness, and purified on silica using gradient elution (chloroform to 5% methanol in chloroform) to provide white crystals of the title compound, 10 mg (20%). ¹H NMR (DMSO-d₆, 500 MHz): 7.68 (2H, m), 7.60 (1H, m), 7.52 (1H, m), 7.22 (1H, m), 7.17 (1H, m), 7.00 (1H, br, s), 6.78 (3H, m), 6.60 (1H, br, s), 4.60 (2H, m), 4.30 (2H, q, 7.2 Hz), 2.18 (6H, s), 1.28 (3H, t, 7.2 Hz); MS (ESI⁺): m/z 437 (M + H)⁺.

Example 2

10 4-[(1*H*-Benzimidazol-2-ylmethyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide

Following the procedure outlined in Step III of example 1, but without triethylamine and substituting 1-ethyl-2-chloromethylbenzimidazole by 2-chloromethylbenzimidazole afforded the title compound with the yield of 51%. ¹H NMR (DMSO-d₆, 500 MHz): 7.70 (2H, m), 7.48 (2H, br, m), 7.13 (2H, m), 7.11 (1H, t, 5.8 Hz), 6.70 (3H, m), 4.52 (2H, d, 5.8 Hz), 2.21 (6H, s); MS (ESI⁺): m/z 409 (M + H)⁺.

Example 3

20 *N*-(4,6-Dimethylpyrimidin-2-yl)-4-[(pyridin-4-ylmethyl)-amino]-benzenesulfonamide

Following the procedure outlined in Step III of example 1 without triethylamine and substituting 1-ethyl-2-chloromethylbenzimidazole by 4-picolylchloride hydrochloride afforded the title compound with the yield of 54%. MS (ESI⁺): m/z 392 (M + Na)⁺, 370 (M + H)⁺.

Example 4

N-(4,6-Dimethylpyrimidin-2-yl)-4-[(1-isobutyl-1*H*-benzimidazol-2-ylmethyl)-amino] -benzenesulfonamide (Compound A)

Following the procedure outlined in example 1, but substituting in step I ethyl
5 bromide for isobutyl iodide, afforded the title compound with stepwise yields of
15%, 95% and 15%. ¹H NMR (DMSO-d₆, 500 MHz): 7.76 (2H, m), 7.70 (1H, m),
7.60 (1H, m), 7.27 (1H, m), 7.22 (1H, m), 7.15 (1H, br, t, 5.3 Hz), 6.86 (2H, m),
6.77 (1H, s), 4.65 (2H, d, 5.3 Hz), 4.13 (2H, d, 7.5 Hz), 2.27 (6H, s), 2.25 (1H, m),
0.91 (6H, d, 6.7 Hz); MS (ESI⁺): m/z 487 (M + Na)⁺, 465 (M + H)⁺.

10 Example 5

yl)- benzenesulfonamide

Following the procedure outlined in example 1, but substituting in step I ethyl
bromide for benzyl bromide, afforded the title compound with stepwise yields of
15 23%, 90% and 18%. ¹H NMR (DMSO-d₆, 500 MHz): 7.81 (2H, m), 7.52 (1H, m),
7.45 (1H, m), 7.30 (5H, m), 7.16 (2H, m), 6.75 (1H, s), 6.54 (2H, m), 6.02 (1H, br,
s), 5.66 (2H, s), 5.63 (2H, s), 2.21 (6H, s); MS (ESI⁺): m/z 521 (M + Na)⁺, 499 (M
+ H)⁺.

Example 6

4-[(1-Ethyl-1*H*-benzimidazol-2-ylmethyl)-amino]-*N*-(5-methoxypyrimidin-2-yl)-benzenesulfonamide

Following the procedure outlined in example 1 step III, but substituting
sulfamethazine by 5-methoxysulfadiazine, afforded the title compound with the

yield of 8%. Dimethylformamide was used as a solvent and additional silica gel chromatography purification with 2:1 petrol ether:ethylacetate was needed. MS (ESI⁺): m/z 461 (M + Na)⁺, 439 (M + H)⁺.

Example 7

- 5 4-[(1H-Benzimidazol-2-ylmethyl)-amino]-N-(pyrimidin-2-yl)-benzenesulfonamide
628 mg (3.8 mmol) sulfadiazine and 728 mg (3.0 mmol) 2-chloromethylbenzimidazole were dissolved in 10 ml 1 M NaOH. Solution was stirred and refluxed for four hours. Reaction mixture was neutralised with addition of 1 M acetic acid until product precipitated. Crystals were filtered and purified on silica
10 using gradient elution (chloroform to 5% methanol in chloroform) to obtain the title compound as white crystals with 38% yield. ¹H NMR (DMSO-d₆, 500 MHz):

6.98 (1H, m), 6.72 (2H, m), 4.53 (2H, 5.7 Hz); MS (ESI⁺): m/z 381 (M + H)⁺.

Example 8

- 15 N-(1H-Benzimidazol-2-ylmethyl)-N-[4-(4,6-dimethylpyrimidin-2-yl)sulfamoyl]-phenyl]-acetamide

18 mg (0.044 mmol) 4-[(1H-benzimidazol-2-ylmethyl)-amino]-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide was dissolved in 2 ml of 15% pyridine in dichloromethane. Acetyl chloride (31 μl, 0.44 mmol) was diluted with 1 ml
20 dichloromethane and solution was added to the reaction mixture. After three hours reaction mixture was washed with acidic water and organic layer was evaporated to dryness. Crystals were purified on silica using gradient elution (chloroform to 5% methanol in chloroform) to obtain white crystals with 30% yield. ¹H NMR (DMSO-d₆, 500 MHz): 7.97 (2H, m), 7.60 (2H, m), 7.48 (2H, m), 7.14 (2H, m),

6.68 (1H, s), 5.08 (2H, s), 2.18 (6H, s), 1.93 (3H, s); MS (ESI⁺): m/z 473 (M + Na)⁺, 451 (M + H)⁺.

Example 9

5 *N*-(1-Acetyl-1*H*-benzimidazol-2-ylmethyl)-*N*-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-acetamide

Title compound was purified from the reaction mixture produced according to example 8 with a yield of 14%. ¹H NMR (DMSO-d₆, 500 MHz): 8.15 (2H, m), 7.80 (2H, m), 7.55 (2H, m), 7.48 (1H, s), 7.21 (3H, m), 5.17 (2H, s), 2.54 (6H, s), 2.03 (3H, s), 1.83 (3H, s); MS (ESI⁺): m/z 493 (M + H)⁺.

10 **Example 10**

4-[(1-Acetyl-1*H*-benzimidazol-2-ylmethyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide

Following the procedure of example 8, but instead of 15% pyridine in dichloromethane only few drops of pyridine in dichloromethane were used as a
15 solvent. Method afforded the title compound with a yield similar to that for *N*-(1*H*-benzimidazol-2-ylmethyl)-*N*-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-acetamide. MS (ESI⁺): m/z 451 (M + H)⁺.

Example 11

4-Benzylamino-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide

20 100 mg (0.36 mmol) sulfamethazine and 70.8 μl (0.60 mmol) benzyl bromide were dissolved in 4 ml methanol. Caesium carbonate (113.4 mg, 0.35 mmol) was added and solution was refluxed overnight with stirring. The reaction mixture was then

evaporated to dryness, and purified on silica using gradient elution (chloroform to 2% methanol in chloroform) to obtain white crystals in a yield similar to that described in example 1 for step III. ¹H NMR (CDCl₃, 500 MHz): 7.93 (2H, m), 7.31 (5H, m), 6.58 (3H, m), 4.36 (2H, s), 2.34 (6H, s); MS (ESI⁺): m/z 369 (M + H)⁺.

Example 12

4-(4-Bromobenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide

Following the procedure outlined in example 11, but substituting benzyl bromide by 4-bromobenzyl bromide, afforded the title compound with a yield of 8%. ¹H NMR (CDCl₃, 500 MHz): 7.91 (2H, m), 7.45 (2H, m), 7.19 (2H, m), 6.59 (1H, s), 6.55 (2H, m), 4.32 (2H, s), 2.34 (6H, s); MS (ESI⁺): m/z 469 (M + Na)⁺, 447 (M + H)⁺.

Example 13

N-(4,6-Dimethylpyrimidin-2-yl)-4-(2-methylbenzylamino)-benzenesulfonamide

15 (Compound B)

Following the procedure outlined in example 11, but substituting benzyl bromide by 2-methylbenzyl bromide, afforded the title compound in a yield similar to that described in example 1 for step III. ¹H NMR (CDCl₃, 500 MHz): 7.95 (2H, m), 7.22 (4H, m), 6.58 (3H, m), 4.30 (2H, s), 2.35 (3H, s), 2.34 (6H, s); MS (ESI⁺): m/z 405 (M + Na)⁺.

Example 14*N*-(4,6-Dimethylpyrimidin-2-yl)-4-(4-methylbenzylamino)-benzenesulfonamide

Following the procedure outlined in example 11, but substituting benzyl bromide by 4-methylbenzyl bromide, afforded the title compound in a yield similar to that
5 described in example 1 for step III. ¹H NMR (CDCl₃, 500 MHz): 7.92 (2H, m), 7.20 (2H, m), 7.15 (2H, m), 6.58 (3H, m), 4.31 (2H, s), 2.34 (3H, s), 2.33 (6H, s); MS (ESI⁺): m/z 405 (M + Na)⁺, 383 (M + H)⁺.

Example 15*N*-(4,6-Dimethylpyrimidin-2-yl)-4-(1-phenylethylamino)-benzenesulfonamide

10 Following the procedure outlined in example 11, but substituting benzyl bromide by (1-bromoethyl)-benzene, afforded the title compound with a yield of 12%. ¹H NMR (CDCl₃, 500 MHz): 7.84 (2H, m), 7.31 (5H, m), 6.57 (1H, s), 6.46 (2H, m), 4.53 (1H, q, 6.7 Hz), 2.30 (6H, s), 1.54 (3H, d, 6.7 Hz); MS (ESI⁺): m/z 405 (M + Na)⁺, 383 (M + H)⁺.

Example 16*N*-(4,6-Dimethylpyrimidin-2-yl)-4-(2-methoxybenzylamino)-benzenesulfonamide

Following the procedure outlined in example 11, but substituting benzyl bromide by 2-methoxybenzyl bromide, afforded the title compound in a yield similar to that described in example 1 for step III. ¹H NMR (CDCl₃, 500 MHz): 7.92 (2H, m),
20 7.25 (2H, m), 6.90 (2H, m), 6.59 (3H, m), 4.36 (2H, s), 3.86 (3H, s), 2.32 (6H, s); MS (ESI⁺): m/z 421 (M + Na)⁺, 399 (M + H)⁺.

Example 17**4-(2,4-Dimethylbenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

Following the procedure outlined in example 11, but substituting benzyl bromide
5 by 2,4-dimethylbenzyl bromide, afforded the title compound with a yield of 23%.
¹H NMR (CDCl₃, 500 MHz): 7.94 (2H, m), 7.14 (1H, m), 7.03 (1H, s), 6.98 (1H, m), 6.58 (3H, m), 4.26 (2H, s), 2.34 (6H, s), 2.31 (3H, s), 2.30 (3H, s); MS (ESI⁺): m/z 419 (M + Na)⁺, 397 (M + H)⁺.

Example 18**N-(4,6-Dimethylpyrimidin-2-yl)-4-(3-methylbenzylamino)-benzenesulfonamide**

Following the procedure outlined in example 11, but substituting benzyl bromide
by 3-methylbenzyl bromide, afforded the title compound with a yield of 10%. ¹H
NMR (CDCl₃, 500 MHz): 7.93 (2H, m), 7.23 (1H, m), 7.11 (3H, m), 6.62 (1H, s),
6.58 (2H, m), 4.31 (2H, s), 2.36 (6H, s), 2.34 (3H, s); MS (ESI⁺): m/z 405 (M +
15 Na)⁺, 383 (M + H)⁺.

Example 19**4-(2,6-Dichlorobenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide
(Compound C)**

Following the procedure outlined in example 11, but substituting benzyl bromide
20 by 2,6-dichlorobenzyl bromide, afforded the title compound with the yield of 10%.
¹H NMR (CDCl₃, 500 MHz): 7.96 (2H, m), 7.34 (2H, m), 7.20 (1H, m), 6.71 (2H, m), 6.59 (1H, s), 4.63 (2H, s), 2.34 (6H, s); MS (ESI⁺): 437 (M + H)⁺.

Example 20

N-(4,6-Dimethylpyrimidin-2-yl)-4-[(naphthalen-2-ylmethyl)-amino]-benzenesulfonamide (Compound D)

Following the procedure outlined in example 11, but substituting benzyl bromide
5 by 2-bromomethylnaphthalene, afforded the title compound with the yield of 20%.
¹H NMR (DMSO-d₆, 500 MHz): 7.85 (4H, m), 7.68 (2H, m), 7.47 (3H, m), 7.19
(1H, t, 5.8 Hz), 6.70 (1H, s), 6.66 (2H, m), 4.49 (2H, d, 5.8 Hz), 2.21 (6H, s); MS
(ESI⁺): m/z 441 (M + H)⁺.

Example 21

10 *N*-(4,6-Dimethylpyrimidin-2-yl)-4-(3-methoxybenzylamino)-benzenesulfonamide

Following the procedure outlined in example 11, but substituting benzyl bromide
by 3-methoxybenzyl bromide, afforded the title compound with the yield of 28%.
¹H NMR (CDCl₃, 500 MHz): 7.93 (2H, m), 6.86 (3H, m), 6.58 (3H, m), 4.33 (2H,
15 s), 3.78 (3H, s), 2.33 (6H, s); MS (ESI⁺): m/z 421 (M + Na)⁺, 399 (M + H)⁺.

Example 22

N-(4,6-Dimethylpyrimidin-2-yl)-4-(4-nitrobenzylamino)-benzenesulfonamide

Following the procedure outlined in example 11, but substituting benzyl bromide
by 4-nitrobenzyl bromide, afforded the title compound with a yield lower than 1%.
20 MS (ESI⁺): m/z 414 (M + H)⁺.

Example 23

N-(4,6-Dimethylpyrimidin-2-yl)-4-(4-trifluoromethylbenzylamino)-
benzenesulfonamide

Following the procedure outlined in example 11, but substituting benzyl bromide
5 by 4-trifluoromethylbenzyl bromide, afforded the title compound in a yield similar
to that described in example 1 for step III. MS (ESI⁺): m/z 459 (M + Na)⁺, 437 (M
+ H)⁺.

Example 24

4-[Bis-(4-trifluoromethylbenzyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-
10 benzenesulfonamide

Title compound was purified from the reaction mixture produced according to
example 23 with the yield of 20%. MS (ESI⁺): 617 m/z (M + Na)⁺, 595 (M + H)⁺.

Example 25

N-(4,6-Dimethylpyrimidin-2-yl)-4-(4-trifluoromethoxybenzylamino)-
15 benzenesulfonamide

Following the procedure outlined in example 11, but substituting benzyl bromide
by 4-trifluoromethoxybenzyl bromide, afforded the title compound with a yield of
25%. MS (ESI⁺): m/z 475 (M + Na)⁺, 453 (M + H)⁺.

Example 26**4-[Bis-(4-trifluoromethoxybenzyl)-amino]-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

Title compound was purified from the reaction mixture produced according to
5 example 25 with a yield of 15%. MS (ESI⁺): m/z 649 (M + Na)⁺, 627 (M + H)⁺.

Example 27**4-(2,5-Dimethylbenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

Following the procedure outlined in example 11 without caesium carbonate and
10 substituting benzyl bromide by 2,5-dimethylbenzyl bromide afforded the title
compound with a yield of 35%. ¹H NMR (CDCl₃, 500 MHz): 7.95 (2H, m), 7.07
(3H, m), 6.59 (3H, m), 4.25 (2H, s), 2.33 (6H, s), 2.30 (3H, s), 2.28 (3H, s); MS
(ESI⁺): m/z 419 (M + Na)⁺.

Example 28

15 **4-(2,6-Dimethylbenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

Following the procedure outlined in example 11 without caesium carbonate and
substituting benzyl bromide by 2,6-dimethylbenzyl bromide afforded the title
compound with a yield of 25%. ¹H NMR (CDCl₃, 500 MHz): 7.99 (2H, m), 7.08
20 (3H, m), 6.62 (3H, m), 4.26 (2H, s), 2.37 (12H, m); MS (ESI⁺): m/z 419 (M +
Na)⁺.

Example 29**4-(3,5-Dimethoxybenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

Following the procedure outlined in example 11 without caesium carbonate and substituting benzyl bromide by 3,5-dimethoxybenzyl chloride afforded the title compound with a yield of 15%. ¹H NMR (CDCl₃, 500 MHz): 7.92 (2H, m), 6.60 (1H, s), 6.58 (2H, m), 6.46 (2H, m), 6.38 (1H, m), 4.30 (2H, s), 3.76 (6H, s), 2.33 (6H, s); MS (ESI⁺): m/z 429 (M + H)⁺.

Example 30**4-(2,5-Dimethoxybenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-****sulfonamide**

Following the procedure outlined in example 11 without caesium carbonate and substituting benzyl bromide by 2,5-methoxybenzyl chloride afforded the title compound with the yield of 13%. Reaction time was three days. ¹H NMR (CDCl₃, 500 MHz): 7.91 (2H, m), 6.79 (3H, m), 6.58 (3H, m), 4.33 (2H, s), 3.81 (3H, s), 3.71 (3H, s), 2.33 (6H, s); MS (ESI⁺): m/z 429 (M + H)⁺.

Example 31**2,6-Dichloro-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide**

Following the procedure outlined in example 11, but substituting benzyl bromide by 2,6-dichlorobenzoyl chloride, afforded the title compound with almost quantitative yield. ¹H NMR (CDCl₃, 500 MHz): 8.11 (2H, m), 7.80 (2H, m), 7.33 (3H, m), 6.59 (1H, s), 2.34 (6H, s); MS (ESI⁺): m/z 473 (M + H)⁺, 451 (M + H)⁺.

Example 32**4-(2-Cyanobenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

Following the procedure outlined in example 11, but substituting benzyl bromide by α -bromo-*o*-tolunitrile, afforded the title compound with a yield of 21%. ¹H
5 NMR (DMSO-d₆, 500 MHz): 7.83 (1H, m), 7.71 (2H, m), 7.65 (1H, m), 7.47 (2H, m), 7.15 (1H, br, t, 5.8 Hz), 6.73 (1H, m), 6.63 (2H, m), 4.50 (2H, d, 5.8 Hz), 2.24 (6H, s); MS (ESI⁺): m/z 416 (M + Na)⁺, 394 (M + H)⁺.

Example 33**4-(2,4-Dimethoxybenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**
10

62 mg (0.37 mmol) 2,4-dimethoxybenzylamine and 100.9 mg (0.50 mmol) sulfamethazine were dissolved in 4 ml of 1,2-dichloroethane. Acetic acid (168 μ l, 2.8 mmol) was added to the reaction mixture and solution was stirred with reflux overnight. Sodium triacetoxyborohydride (162.9 mg, 0.77 mmol) was dissolved to
15 the reaction solution and refluxing was continued for three hours. The reaction mixture was then evaporated to dryness, and purified on silica using gradient elution (chloroform to 2% methanol in chloroform) and 2:1 petrol ether:ethylacetate to obtain the title compound as white crystals with a yield of 10%. ¹H NMR (CDCl₃, 500 MHz): 7.91 (2H, m), 7.13 (1H, m), 6.58 (3H, m),
20 6.47 (1H, m), 6.42 (1H, m), 4.53 (1H, t, 5.0 Hz), 4.30 (2H, d, 5.0 Hz), 3.82 (3H, s), 3.79 (3H, s), 2.33 (6H, s); MS (ESI⁺): m/z 429 (M + H)⁺.

Example 34

N-(4,6-Dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-indol-3-ylmethyl)-amino]-benzenesulfonamide (Compound F)

1-ethylindole-3-carboxaldehyde was prepared from alkylation reaction of indole-3-carboxaldehyde. Indole-3-carboxaldehyde (900 mg, 6.2 mmol) was dissolved in 5 ml dimethylformamide, ethyl bromide (918 μ l, 12 mmol) and sodium hydride (282.8 mg, 12 mmol) were added to the reaction mixture. Solution was stirred and refluxed for three hours. The reaction mixture was then evaporated to dryness and washed with water. Pale brown crystals were obtained with 80% yield.

Following the procedure outlined in example 33, but substituting 2,4-dimethoxybenzylaldehyde by 1-ethylindole-3-carboxaldehyde, afforded the compound *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-indol-3-ylmethyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide. Instead of sodium triacetoxyborohydride sodium borohydride was used to reduce the imine intermediate. ¹H NMR (CDCl₃, 500 MHz): 7.88 (2H, m), 7.52 (1H, m), 7.29 (1H, m), 7.18 (1H, m), 7.05 (1H, m), 7.03 (1H, s), 6.56 (2H, m), 6.52 (1H, s), 4.41 (2H, d, 4.7 Hz), 4.33 (1H, t, 4.7 Hz), 4.08 (2H, q, 7.3 Hz), 2.27 (6H, s), 1.38 (3H, t, 7.3 Hz); MS (ESI⁺): m/z 458 (M + Na)⁺.

Example 35

N-[4-(4,6-Dimethylpyrimidin-2-yl)sulfamoyl]-phenyl]-2-(2-methoxyphenyl)-acetamide

2-Methoxyphenylacetic acid (33 mg, 0.20 mmol) and sulfamethazine (55 mg, 0.20 mmol) were dissolved in 4 ml of chloroform. Triethylamine (70 μ l, 0.55 mmol) and diisopropylcarbodiimide (50 μ l, 0.20 mmol) were added to the reaction mixture. Solution was stirred and refluxed overnight. The reaction mixture was

then evaporated to dryness, washed with water and purified on silica using gradient elution (chloroform to 2% methanol in chloroform) to obtain white crystals with the yield of 40%. ¹H NMR (CDCl₃, 500 MHz): 8.04 (2H, m), 7.54 (2H, m), 7.30 (2H, m), 6.98 (2H, m), 6.60 (1H, s), 3.95 (3H, s), 3.72 (2H, s), 2.33 (6H, s); MS (ESI⁺): m/z 449 (M + Na)⁺, 427 (M + H)⁺.

Example 36

2-Acetyl-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide

Following the procedure outlined in example 35, but substituting 2-methoxyphenylacetic acid by 2-acetylbenzoic acid, afforded the title compound with a yield of 11%. MS (ESI⁺): m/z 447 (M + Na)⁺, 425 (M + H)⁺.

Example 37

1-Methyl-1H-indole-2-carboxylic acid [4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-amide

Following the procedure outlined in example 35, but substituting 2-methoxyphenylacetic acid by 1-methylindole-2-carboxylic acid and using dimethylformamide as a solvent afforded the title compound with a yield similar to that of N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-2-(2-methoxyphenyl)-acetamide. MS (ESI⁺): m/z 458 (M + Na)⁺.

Example 38**2-(3,5-Dimethoxyphenyl)-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-acetamide**

Following the procedure outlined in example 35, but substituting 2-methoxyphenylacetic acid by 3,5-dimethoxyphenylacetic acid, afforded the title compound with a yield of 54%. MS (ESI⁺): m/z 457 (M + H)⁺.

Example 39**N-(4,6-Dimethylpyrimidin-2-yl)-4-[2-(2-methoxyphenyl)-ethylamino]-benzenesulfonamide (Compound G)**

33 mg (0.08 mmol) N-[4-(4,6-dimethylpyrimidin-2-ylsulfomoyl)-phenyl]-2-(2-methoxyphenyl)-acetamide was dissolved in 2 ml tetrahydrofuran. 2 ml of a 0.1 M borane tetrahydrofuran complex was added to the reaction mixture under nitrogen atmosphere and solution was stirred overnight with reflux. Reaction was quenched with 6 M HCl and the reaction mixture was neutralised with 1 M NaOH. Product was extracted with chloroform and purified on silica using gradient elution (chloroform to 2% methanol in chloroform) to obtain white crystals with a yield of 20%. ¹H NMR (CDCl₃, 500 MHz): 7.92 (2H, m), 7.22 (1H, m), 7.12 (1H, m), 6.89 (2H, m), 6.60 (1H, br, s), 6.54 (2H, m), 3.85 (3H, s), 3.38 (2H, t, 6.9 Hz), 2.93 (2H, t, 6.9 Hz), 2.33 (6H, s); MS (ESI⁺): m/z 435 (M + Na)⁺, 413 (M + H)⁺.

Example 40**4-[2-(3,5-Dimethoxyphenyl)-ethylamino]-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

Following the procedure outlined in example 39, but substituting *N*-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-2-(2-methoxyphenyl)-acetamide by 2-(3,5-dimethoxyphenyl)-*N*-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-acetamide, afforded the title compound with a yield of 11%. ¹H NMR (CDCl₃, 500 MHz): 7.92 (2H, m), 6.58 (1H, s), 6.54 (2H, m), 6.34 (3H, s), 4.20 (1H, t, 5.8 Hz), 3.76 (6H, s), 3.42 (2H, m), 2.85 (2H, t, 6.9 Hz), 2.34 (6H, s); MS (ESI⁺): m/z 465 (M + Na)⁺, 443 (M + H)⁺.

Example 41**4-(Benzhydrylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide (Compound H)**

Sulfamethazine (105 mg, 0.38 mmol) and diphenylchloromethane (77 μl, 0.38 mmol) were dissolved in 3 ml pyridine. Solution was stirred and refluxed overnight. The reaction mixture was evaporated to dryness and dissolved to 1 M NaOH. Product was precipitated with 1 M acetic acid. Precipitation cycle was repeated for three times to give white crystals of the title compound with a yield of 8%. MS (ESI⁺): m/z 467(M + Na)⁺, 445 (M + H)⁺.

Example 42**4-(4-Aminobenzylamino)-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide**

18 mg (0.04 mmol) of *N*-(4,6-dimethylpyrimidin-2-yl)-4-(4-nitrobenzylamino)-benzenesulfonamide was dissolved in 1 ml of tetrahydrofuran. Hydrazinium

hydrate (50 μ l, 1.5 mmol) and catalytic amount of palladium on charcoal were added to the reaction mixture. Solution was stirred overnight. The reaction mixture was evaporated to dryness and purified on silica using gradient elution (chloroform to 4% methanol in chloroform) to obtain with a yield of 59%. MS (ESI⁺): m/z 406 (M + H)⁺, 384 (M + H)⁺.

Example 43

4-[[4-(4,6-Dimethylpyrimidin-2-ylsulfamoyl)-phenylamino]-methyl]-benzamide
4-[[4-(4,6-Dimethylpyrimidin-2-ylsulfamoyl)-phenylamino]-methyl]-benzoic acid methyl ester was prepared like described on example 11 and was treated with 25% ammonia to obtain the title compound with a yield lower than 1%. ¹H NMR (CDCl₃, 500 MHz): 7.81 (2H, m), 7.67 (2H, m), 7.37 (2H, m), 7.12 (1H, br, t, 6.0
412 (M + H)⁺.

Example 44

4-[[[(2,6-Dichloro-phenyl)-hydroxy-methyl]-amino]-N-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide
11 mg (0.02 mmol) of 2,6-dichloro-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide was dissolved in 2 ml tetrahydrofurane. Lithium aluminium hydride (6 mg, 0.16 mmol) was added to the reaction mixture under nitrogen atmosphere and solution was stirred overnight. The reaction mixture was filtered, evaporated to dryness and purified by on silica using gradient elution (chloroform to 4% methanol in chloroform) to obtain the title compound with a yield of 18%. MS (ESI⁺): m/z 475 (M + Na)⁺.

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are
5 illustrative and should not be construed as restrictive.

REFERENCES

- Cheng, Y., and Prusoff, W.H., 1973. *Biochem. Pharmacol.* 22: 3099
- Jasper, J.R., Lesnick, J.D., Chang, L.K., Yamanashi, S.S., Chang, T.C., Hsu, S.A.O., Daunt, D.A., Bonhaus, D.W., and Egen, R.M., 1998. *Biochem. Pharmacol.*
10 55: 1035
- Regan, J.W., and Scheinin, M., 1992. *Biochem. Biophys. Acta* 1134: 169
- Marjamäki, A., Pihlavisto, M., Cockcroft, V., Heinonen, P., Savola, J.-M., and Scheinin, M., 1998. *Mol. Pharmacol.* 53: 370
- 15 Pohjanoksa, K., Jansson, C.C., Luomala, K., Marjamäki, A., Savola, J.-M., and Scheinin, M., 1997. *Eur. J. Pharmacol.* 35: 53
- Tian, W.-N., Duzic, E., Lanier, S.M., and Deth, R.C., 1993. *Mol. Pharmacol.* 45: 524
- Kumar, V.B., Reddy, M.V., *Indian J. Chem., Sect. B* (1985), 24B(12), 1298-1301
- 20 Farag, A.M., El-Mouafi, H.M., Khalifa, M., 1991. *Egypt. J. Pharm. Sci.* 32 (3-4), 951-9
- Wieland, T., and Jakobs, K.H., 1994. *Meth. Enzymol.* 237: 3


Heinonen et al.1999, The Journal of Clinical Endocrinology & Metabolism,
84:2429

Link R E et al., 1996, Science 273:803

MacMillan L B et al., 1996, Science 273:801

CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof wherein

- 5 **R₁** , **R₂** , **R₃** , **R₄** and **R₅** are independently of each other H , a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;
- X** is H , a straight or branched alkyl chain with 1 to 4 carbon atoms, phenyl or
- Z** is H , acetyl, -CH₂-Ph-O-CF₃ or -CH₂-Ph-CF₃ , were Ph is phenyl;
- 10 **Y** is a ring structure optionally linked to formula (I) with an alkyl chain having one or two carbon atoms, wherein the ring structure is
- a) phenyl optionally mono- or disubstituted and each substituent is independently selected from the group consisting of a halogen, a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, a halogen substituted methyl or methoxy group, a nitrile, an amide, amino, or a nitro group;
- b) 2-benzimidazolyl, 2-imidazolyl, or 2- or 3-indolyl, wherein one N optionally has a substituent that is a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, or benzyl; and wherein the
- 20 2-benzimidazolyl, 2-imidazolyl, or 2- or 3-indolyl is optionally mono- or

disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

(c) pyridinyl optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen; or

(d) naphthyl optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

excluding 4-[(1*H*-benzimidazol-2-ylmethyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-methyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide and *N*-(4-methyl-2-pyrimidinyl)-4-[(1*H*-benzimidazol-2-ylmethyl)-amino]-benzene-

2. A compound of formula (I) according to claim 1 wherein R_1 and R_3 are methyl and R_2 , R_4 and R_5 are H.

3. A compound of formula (I) according to claim 1 or 2 wherein X is H, Y is a phenyl optionally mono- or disubstituted with a straight or branched alkoxy group and Z is H.

4. A compound of formula (I) according to claim 2 and 3 wherein said phenyl is substituted and said alkoxy substituent is methoxy selected from the group consisting of 4-(2,4-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(3-methoxybenzylamino)-benzenesulfonamide, 4-(3,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-


benzenesulfonamide, 4-(2,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide and *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2-methoxybenzylamino)-benzenesulfonamide.

5 5. A compound of formula (I) according to claim 1 or 2 wherein **X** is H, **Y** is a phenyl optionally mono- or disubstituted with a straight or branched alkyl and/or a halogen and **Z** is H.

6. A compound of formula (I) according to claim 2 and 5 wherein said compound is selected from the group consisting of 4-benzylamino-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2-methylbenzylamino)-benzenesulfonamide, 4-(2,4-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(3-methylbenzylamino)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(2,6-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(4-bromobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide and 4-(2,6-dichlorobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide.

7. A compound of formula (I) according to claim 2 selected from the group consisting of *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-indol-3-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-isobutyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(1-phenylethylamino)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[2-(2-methoxyphenyl)-ethylamino]-benzenesulfonamide and *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(naphthalen-2-ylmethyl)-amino]-benzenesulfonamide.

8. Use of a compound of formula (I)



or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal wherein

R_1 , R_2 , R_3 , R_4 and R_5 are independently of each other H, a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

X is H, a straight or branched alkyl chain with 1 to 4 carbon atoms, phenyl or $-OH$ or $=O$.

10 Z is H, acetyl, $-CH_2-Ph-O-CF_3$ or $-CH_2-Ph-CF_3$, where Ph is phenyl;

Y is a ring structure optionally linked to formula (I) with an alkyl chain having one or two carbon atoms, wherein the ring structure is

a) phenyl optionally mono- or disubstituted and each substituent is independently selected from the group consisting of a halogen, a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, a halogen substituted methyl or methoxy group, an acetyl, a nitrile, an amide, amino, or a nitro group;

b) 2-benzimidazolyl, 2-imidazolyl, or 2- or 3-indolyl, wherein one N optionally has a substituent that is a straight or branched alkyl or alkoxy chain with 1 to 4 carbon atoms, or benzyl; and wherein the 2-benzimidazolyl, 2-imidazolyl or 2- or 3-indolyl is optionally mono- or

disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

(c) pyridinyl optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen; or

(d) naphthyl optionally mono- or disubstituted and each substituent can independently be a straight or branched alkyl or alkoxy group with 1 to 4 carbon atoms, or a halogen;

excluding *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-methyl-1*H*-benzimidazol-2-ylmethyl)-amino] -benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-benzimidazol-2-ylmethyl)-amino] -benzenesulfonamide and *N*-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-4-ethoxy-benzamide.

according to claim 8 wherein **R**₁ and **R**₃ are methyl and **R**₂, **R**₄ and **R**₅ are H.

10. Use of compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 8 or 9 wherein **X** is H, **Y** is a phenyl optionally mono- or disubstituted with a straight or branched alkoxy group and **Z** is H.

11. Use of compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 9 and 10 wherein said phenyl is substituted and said alkoxy substituent is methoxy and said compound is selected from the group consisting of 4-(2,4-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-(3-methoxybenzylamino)-benzenesulfonamide, 4-(3,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzene-

sulfonamide, 4-(2,5-dimethoxybenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide and *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2-methoxybenzylamino)-benzenesulfonamide.

12. Use of compound of formula (I) or a pharmaceutically acceptable salt thereof
5 according to claim 8 or 9 wherein **X** is H, **Y** is a phenyl optionally mono- or disubstituted with a straight or branched alkyl and/or a halogen, and **Z** is H.

13. Use of compound of formula (I) or a pharmaceutically acceptable salt thereof
according to claim 9 and 12 wherein said compound is selected from the group
consisting of 4-benzylamino-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide,
10 *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2-methylbenzylamino)-benzenesulfonamide,
4-(2,4-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide,
N-(4,6-dimethylpyrimidin-2-yl)-4-(3-methylbenzylamino)-

benzenesulfonamide, 4-(2,5-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide,
15 *N*-(4,6-dimethylpyrimidin-2-yl)-4-(2,6-dimethylbenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, 4-(4-bromobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide and 4-(2,6-dichlorobenzylamino)-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide.

14. Use of a compound of formula (I) or a pharmaceutically acceptable salt
20 thereof according to claim 9 wherein said compound is selected from the group consisting of 4-[(1*H*-benzimidazol-2-ylmethyl)-amino]-*N*-(4,6-dimethylpyrimidin-2-yl)-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-ethyl-1*H*-indol-3-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(1-isobutyl-1*H*-benzimidazol-2-ylmethyl)-amino]-benzenesulfonamide, *N*-(4,6-
25 dimethylpyrimidin-2-yl)-4-(1-phenylethylamino)-benzenesulfonamide, *N*-(4,6-

dimethylpyrimidin-2-yl)-4-[2-(2-methoxyphenyl)-ethylamino]-benzenesulfonamide and *N*-(4,6-dimethylpyrimidin-2-yl)-4-[(naphthalen-2-ylmethyl)-amino]-benzenesulfonamide.

15. The use according to any of claims 8 to 14, wherein the disease is a coronary
5 heart disease (CHD).

16. The use according to any of claims 8 to 14, wherein the disease is

- acute myocardial infarction (AMI),
- unstable angina pectoris,
- Prinzmetal's variant form of angina pectoris,
- 10 - other forms of chronic angina pectoris and CHD, or
- restenosis after coronary angioplasty.

17. The use according to any of claims 8 to 14, wherein the disease is essential hypertension.

18. The use according to any of claims 8 to 14, wherein the disease is a vascular
15 disease, which is

vasoconstriction or hypoxic brain damage subsequent to subarachnoid haemorrhage,

migraine,

Raynaud's disease or cold intolerance,

20 pre-eclampsia,

male erectile dysfunction, or

obesity.

19. The use according to any of claims 8 to 14, wherein said alpha-2B-adrenoceptor antagonist is administered to a mammal to potentiate the clinical efficacy of an anaesthetic and/or analgetic alpha-2-adrenoceptor agonist, said agonist not being selective for the alpha-2B-adrenoceptor subtype.
- 5 20. The use according to any of claims 8 to 14, wherein said alpha-2B-adrenoceptor antagonist is administered to an individual having a deletion of 3 glutamates from the glutamic acid repeat element of 12 glutamates (amino acids 297–309), in an acid stretch of 17 amino acids, located in the third intracellular loop of the receptor polypeptide.
- 10 21. The use according to claim 20 wherein said individual is a deletion/deletion genotype.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/FI 02/00643

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/69 C07D403/12 A61K31/635 A61P9/10 A61P9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 58454 A (OY JUVANTIA PHARMA LTD) 16 August 2001 (2001-08-16) the whole document	1-21
P,X	--- DATABASE STN INTERNATIONAL [Online] FILE CAPLUS; SANKYO COMPANY LTD: "Preparation of nitrophenylcarboxamide derivatives as non-tyrosine proliferator-activated receptor retrieved from CAPLUS, accession no. 2001:816614 Database accession no. 135:357944 XP002902751 abstract & WO 01 83427 A (SANKYO COMPANY LTD) 8 November 2001 (2001-11-08) --- -/--	1-21

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 2002

Date of mailing of the international search report

01.11.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gerd Strandell

INTERNATIONAL SEARCH REPORT

onal Application No
PCT/FI 02/00643

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE STN INTERNATIONAL [Online] FILE CHEMCATS, order number AE-848/12530187; CAS Registry no. 380644-35-9, 1 July 2001 (2001-07-01) "Benzenesulfonamide, 4-[1(1-methyl-1H-benzimidazol-2-yl)methyl] amino]-N-(4-methyl-2-pyrimidinyl)-" retrieved from CHEMCATS, accession no. 2002:1405436 XP002902752 abstract</p>	1
A	<p>US 5 292 740 A (BURRI KASPAR ET AL) 8 March 1994 (1994-03-08) the whole document</p>	1-21
A	<p>RAJENDRA S. VARMA ET AL: "Potential biologically active agents. XII. Synthesis and antibacterial activity of substituted p-methylamino-benzenesulfonamides." JOURNAL INDIAN CHEM. SOC., vol. 55, no. 7, July 1978 (1978-07), pages 716-718, XP002902753 the whole document</p>	1-21
A	<p>DATABASE STN INTERNATIONAL [Online]</p>	1-21
A	<p>BEDENKO V. ET AL: "N4-acylsulfonamides. I. Derivatives of +- (2-ethoxybenzamido) benzenesulfonamide." retrieved from CAPLUS, accession no. 1967:411468 Database accession no. 67:11468 XP002902754 abstract & CROAT. CHEM. ACTA., vol. 38, 1966, pages 309-311,</p> <p>US 6 150 389 A (MUNK S A ET AL) 21 November 2000 (2000-11-21) the whole document</p>	1-21

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No

PCT/FI 02/00643

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0158454	A	16-08-2001	AU 3551001 A	20-08-2001
			WO 0158454 A1	16-08-2001
			US 2002058618 A1	16-05-2002

WO 0183427	A	08-11-2001	AU 5261201 A	12-11-2001
			WO 0183427 A1	08-11-2001

US 5292740	A	08-03-1994	AT 197044 T	15-11-2000
			AU 653604 B2	06-10-1994
			AU 1812192 A	17-12-1992
			BG 60831 B2	30-04-1996
			CA 2071193 A1	14-12-1992
			CS 9201804 A3	16-12-1992
			DE 59209872 D1	23-11-2000
			DK 526708 T3	12-02-2001
			EE 3028 B1	15-08-1997
			EP 0526708 A1	10-02-1993
			ES 2152222 T3	01-02-2001
			FI 922746 A	14-12-1992
			HU 63152 A2	28-07-1993
			HU 9500261 A3	28-09-1995
			IE 921920 A1	16-12-1992
			IL 102138 A	12-09-1996
			JP 1997825 C	08-12-1995
			JP 5222003 A	31-08-1993
			JP 7030042 B	05-04-1995
			NO 922323 A	14-12-1992
			NZ 263074 A	25-11-1994

			RO 111268 B	30-08-1996
			SG 54209 A1	16-11-1998
			SK 279006 B6	06-05-1998
			BR 9202219 A	02-02-1993
			KR 235507 B1	15-12-1999
			MX 9202747 A1	31-05-1994
			RU 2086544 C1	10-08-1997
			ZA 9204126 A	24-02-1993

US 6150389	A	21-11-2000	US 5731337 A	24-03-1998
			US 6319935 B1	20-11-2001
			US 2002049241 A1	25-04-2002
			AU 687584 B2	26-02-1998
			AU 3007695 A	09-02-1996
			CA 2194702 A1	25-01-1996
			DE 69524223 D1	10-01-2002
			DE 69524223 T2	22-08-2002
			EP 0770068 A1	02-05-1997
			ES 2168373 T3	16-06-2002
			JP 10502643 T	10-03-1998
			WO 9601813 A1	25-01-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.